Clinical-scale Lentiviral Vector Transduction of PBL for TCR Gene Therapy and Potential for Expression in Less-differentiated Cells

In human gene therapy applications, lentiviral vectors may have advantages over gamma-retroviral vectors because of their ability to transduce nondividing cells, their resistance to gene silencing, and a lack of integration site preference. In this study, we used VSV-G pseudotype third generation lentiviral vectors harboring specific antitumor T-cell receptor (TCR) to establish clinical-scale lentiviral transduction of peripheral blood lymphocyte (PBL). Spinoculation (1000g, 32°C for 2 h) in the presence of protamine sulfate represents the most efficient and economical approach to transduce a large number of PBLs compared with RetroNectin-based methods. Up to 20 million cells per well of a 6-well plate were efficiently transduced and underwent an average 50-fold expansion in 2 weeks. TCR transduced PBL-mediated specific antitumor activities including interferon-γ release and cell lysis. Compared with gamma-retroviral vectors, the TCR transgene could be preferentially expressed on a less-differentiated cell population.

[1]  S. Rosenberg,et al.  Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition , 2008, Gene Therapy.

[2]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[3]  T. Schumacher,et al.  T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model , 2008, Journal of immunotherapy.

[4]  A. Schambach,et al.  Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  M. Sadelain,et al.  The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  Donald B Kohn,et al.  Lentiviral vectors ready for prime-time , 2007, Nature Biotechnology.

[7]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[8]  S. Rosenberg,et al.  Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1 , 2006, The Journal of Immunology.

[9]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[10]  V. Baekelandt,et al.  Comparison of lentiviral vector titration methods , 2006, BMC biotechnology.

[11]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[12]  A. Schambach,et al.  Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression , 2006, Gene Therapy.

[13]  S. Rosenberg,et al.  Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR , 2005, The Journal of Immunology.

[14]  J. Ellis.  Silencing and variegation of gammaretrovirus and lentivirus vectors. , 2005, Human gene therapy.

[15]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[16]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[17]  Richard A. Morgan,et al.  Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines , 2005, The Journal of Immunology.

[18]  Mark M Davis,et al.  How T cells 'see' antigen , 2005, Nature Immunology.

[19]  P. Kourilsky,et al.  Lineage relationships, homeostasis, and recall capacities of central– and effector–memory CD8 T cells in vivo , 2005, The Journal of experimental medicine.

[20]  M. Wiznerowicz,et al.  Harnessing HIV for therapy, basic research and biotechnology. , 2005, Trends in biotechnology.

[21]  W. Kao,et al.  Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  S. Rosenberg,et al.  High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens , 2003, The Journal of Immunology.

[23]  L. Naldini,et al.  Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. , 2003, Blood.

[24]  E. Lam,et al.  Commitment Point during G0→G1 That Controls Entry into the Cell Cycle , 2003, Molecular and Cellular Biology.

[25]  J. Thomson,et al.  High‐Level Sustained Transgene Expression in Human Embryonic Stem Cells Using Lentiviral Vectors , 2003, Stem cells.

[26]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[27]  E. Robinet,et al.  Influence of ex vivo expansion and retrovirus-mediated gene transfer on primary T lymphocyte phenotype and functions. , 2002, Journal of hematotherapy & stem cell research.

[28]  T. Schumacher,et al.  T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.

[29]  I. Verma,et al.  Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Melo,et al.  Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. , 2002, Blood.

[31]  David Baltimore,et al.  Germline Transmission and Tissue-Specific Expression of Transgenes Delivered by Lentiviral Vectors , 2002, Science.

[32]  N. Taylor,et al.  Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap , 2001, Gene Therapy.

[33]  B. N. Day,et al.  Flow cytometric cell cycle analysis of cultured porcine fetal fibroblast cells. , 1999, Biology of reproduction.

[34]  David A. Williams,et al.  High-Efficiency Gene Transfer into Normal and Adenosine Deaminase-Deficient T Lymphocytes Is Mediated by Transduction on Recombinant Fibronectin Fragments , 1998, Journal of Virology.

[35]  T. Hawley,et al.  Versatile retroviral vectors for potential use in gene therapy. , 1994, Gene therapy.

[36]  K. Titani,et al.  Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. , 1991, Journal of biochemistry.

[37]  S. Rosenberg,et al.  Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. , 1989, Journal of immunology.

[38]  R. Jaenisch,et al.  Chromosomal position or virus mutation permits retrovirus expression in embryonal carcinoma cells , 1986, Cell.

[39]  S. Goff,et al.  Isolation of a recombinant murine leukemia virus utilizing a new primer tRNA , 1986, Journal of virology.